Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Cash from Investing Activities for 17 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 28.55% year-over-year to $34.2 million; the TTM figure through Jun 2026 stood at $47.0 million (up 221.67% YoY), while the FY2025 annual figure was $32.3 million, up 111.78% from the prior year.
• Cash from Investing Activities fell to $34.2 million in Q2 2026 per MDGL's latest filing, from $192.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $192.2 million in Q1 2026 and bottomed at -$362.1 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$17.3 million across 5 years, with a median of $30.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 324.39% — and 2024, when it plunged 3171.65%.
• Madrigal Pharmaceuticals' Cash from Investing Activities stood at $66.4 million in 2022, then sank by 645.47% to -$362.1 million in 2023, then surged by 86.76% to -$47.9 million in 2024, then soared by 157.52% to $27.6 million in 2025, then increased by 23.98% to $34.2 million in 2026.
• Business Quant data shows MDGL's Cash from Investing Activities at $34.2 million in Q2 2026, $192.2 million in Q1 2026, and $27.6 million in Q4 2025.